Bioverativ

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Biopharma Dive
Thu, 06/20/19 - 10:04 am
Sanofi
M&A
Bioverativ
hemophilia
gene therapy
Sanofi's Eloctate, a Bioverativ buyout centerpiece, suffers on Roche's Hemlibra launch
Fierce Pharma
Fri, 04/26/19 - 07:39 pm
Sanofi
Bioverativ
M&A
diabetes
Eloctate
Roche
Hemlibra
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
Thu, 07/5/18 - 10:28 pm
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
Sat, 04/28/18 - 12:18 pm
M&A
Takeda
Shire
Novartis
AveXis
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Analyzing the orphan drugs market ($127bn)
GoinPharma
Fri, 03/2/18 - 09:48 am
orphan drugs
Shire
Baxalta
Sanofi
Bioverativ
M&A
Bioverativ inks $100M gene therapy deal with Oxford BioMedica
Endpoints
Thu, 02/15/18 - 10:06 am
Bioverativ
gene therapy
Oxford BioMedica
Sanofi
How did Sanofi win over Bioverativ? It upped its bid—and called on activist investor Alex Denner
Fierce Pharma
Sat, 02/10/18 - 09:30 am
Sanofi
Bioverativ
M&A
Alex Denner
Bioverativ execs haul in new fortunes after patiently waiting for Sanofi to bid up its $11.6B exclusive buyout
Endpoints
Fri, 02/9/18 - 10:07 am
Sanofi
Bioverativ
executive pay
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
Market Realist
Wed, 02/7/18 - 10:56 pm
Sanofi
hemophilia
Bioverativ
M&A
Sanofi CEO: $16 Billion Deal Binge Does Not Represent A Change In Strategy
Forbes
Mon, 01/29/18 - 03:26 pm
Sanofi
Pharma CEOs
Olivier Brandicourt
M&A
Ablynx
Bioverativ
[video]Big Biotech Is Bustling With Buyouts
Motley Fool
Mon, 01/29/18 - 09:21 am
biotech
M&A
Celgene
Juno Therapeutics
Sanofi
Bioverativ
U.S. SEC files suit over possible insider trading on Sanofi's purchase of Bioverativ
Yahoo/Reuters
Sat, 01/27/18 - 09:33 am
SEC
insider trading
Sanofi
M&A
Bioverativ
Biotech M&A In 2018: A Tsunami Or A Ripple?
Forbes
Tue, 01/23/18 - 09:22 am
biotech
M&A
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Sanofi to Buy Biogen Hemophilia Spinoff for $11.6 Billion
Bloomberg
Mon, 01/22/18 - 11:05 am
Sanofi
M&A
Bioverativ
Biogen
hemophilia
Sanofi near deal to buy Bioverativ for more than $11.5 bln -WSJ
Yahoo/Reuters
Sun, 01/21/18 - 09:07 pm
Sanofi
M&A
Bioverativ
Disruption of the Year: Long-Acting Hemophilia Drugs
BioPharma Dive
Tue, 12/5/17 - 09:34 am
hemophilia
Eloctate
Kovaltry
Bayer
Bioverativ
Bioverativ and Bicycle keep rare disease deals rolling
BioPharma Dive
Thu, 09/7/17 - 09:39 am
Bioverativ
Bicycle Therapeutics
R&D
drug development
sickle cell disease
hemophilia
Bioverativ taps patient social network for input on hemophilia trial design
Fierce Pharma
Thu, 08/24/17 - 10:41 pm
Bioverativ
social media
clinical trials
patients
hemophilia A
Biogen
Biogen's hemophilia business spin-off will trade on its own starting Thursday
Marketwatch
Wed, 02/1/17 - 10:34 am
Biogen
spinoffs
Bioverativ
hemophilia
Biogen spinoff begins trading today; New oncology chief at AstraZeneca
Endpoints
Fri, 01/13/17 - 11:18 am
Biogen
AstraZeneca
oncology
hemophilia
Bioverativ

Pages